This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Skiadopoulos, M. H.
Right arrow Articles by Murphy, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Skiadopoulos, M. H.
Right arrow Articles by Murphy, B. R.

 Previous Article  |  Next Article 

Journal of Virology, February 1999, p. 1374-1381, Vol. 73, No. 2
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Identification of Mutations Contributing to the Temperature-Sensitive, Cold-Adapted, and Attenuation Phenotypes of the Live-Attenuated Cold-Passage 45 (cp45) Human Parainfluenza Virus 3 Candidate Vaccine

Mario H. Skiadopoulos,1,* Sonja Surman,1 Joanne M. Tatem,2 Maribel Paschalis,2 Shin-Lu Wu,2 Stephen A. Udem,2 Anna P. Durbin,1 Peter L. Collins,1 and Brian R. Murphy1

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892,1 and Wyeth-Lederle Vaccines and Pediatrics, Pearl River, New York 109652

Received 25 August 1998/Accepted 20 October 1998

The live-attenuated human parainfluenza virus 3 (PIV3) cold-passage 45 (cp45) candidate vaccine was shown previously to be safe, immunogenic, and phenotypically stable in seronegative human infants. Previous findings indicated that each of the three amino acid substitutions in the L polymerase protein of cp45 independently confers the temperature-sensitive (ts) and attenuation (att) phenotypes but not the cold-adaptation (ca) phenotype (29). cp45 contains 12 additional potentially important point mutations in other proteins (N, C, M, F, and hemagglutinin-neuraminidase [HN]) or in cis-acting sequences (the leader region and the transcription gene start [GS] signal of the N gene), and their contribution to these phenotypes was undefined. To further characterize the genetic basis for the ts, ca, and att phenotypes of this promising vaccine candidate, we constructed, using a reverse genetics system, a recombinant cp45 virus that contained all 15 cp45-specific mutations mentioned above, and found that it was essentially indistinguishable from the biologically derived cp45 on the basis of plaque size, level of temperature sensitivity, cold adaptation, level of replication in the upper and lower respiratory tract of hamsters, and ability to protect hamsters from subsequent wild-type PIV3 challenge. We then constructed recombinant viruses containing the cp45 mutations in individual proteins as well as several combinations of mutations. Analysis of these recombinant viruses revealed that multiple cp45 mutations distributed throughout the genome contribute to the ts, ca, and att phenotypes. In addition to the mutations in the L gene, at least one other mutation in the 3' N region (i.e., including the leader, N GS, and N coding changes) contributes to the ts phenotype. A recombinant virus containing all the cp45 mutations except those in L was more ts than cp45, illustrating the complex nature of this phenotype. The ca phenotype of cp45 also is a complex composite phenotype, reflecting contributions of at least three separate genetic elements, namely, mutations within the 3' N region, the L protein, and the C-M-F-HN region. The att phenotype is a composite of both ts and non-ts mutations. Attenuating ts mutations are located in the L protein, and non-ts attenuating mutations are located in the C and F proteins. The presence of multiple ts and non-ts attenuating mutations in cp45 likely contributes to the high level of attenuation and phenotypic stability of this promising vaccine candidate.


* Corresponding author. Mailing address: NIH, Bldg. 7, Rm. 100, 7 Center Dr., MSC 0720, Bethesda, MD 20892-0720. Phone: (301) 496-3399. Fax: (301) 496-8312. E-mail: mskiadopoulos{at}atlas.niaid.nih.gov.


Journal of Virology, February 1999, p. 1374-1381, Vol. 73, No. 2
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Bukreyev, A., Rollin, P. E., Tate, M. K., Yang, L., Zaki, S. R., Shieh, W.-J., Murphy, B. R., Collins, P. L., Sanchez, A. (2007). Successful Topical Respiratory Tract Immunization of Primates against Ebola Virus. J. Virol. 81: 6379-6388 [Abstract] [Full Text]  
  • Bukreyev, A., Skiadopoulos, M. H., Murphy, B. R., Collins, P. L. (2006). Nonsegmented negative-strand viruses as vaccine vectors.. J. Virol. 80: 10293-10306 [Full Text]  
  • Rumyantsev, A. A., Murphy, B. R., Pletnev, A. G. (2006). A Tick-Borne Langat Virus Mutant That Is Temperature Sensitive and Host Range Restricted in Neuroblastoma Cells and Lacks Neuroinvasiveness for Immunodeficient Mice. J. Virol. 80: 1427-1439 [Abstract] [Full Text]  
  • Brown, D. D., Rima, B. K., Allen, I. V., Baron, M. D., Banyard, A. C., Barrett, T., Duprex, W. P. (2005). Rational Attenuation of a Morbillivirus by Modulating the Activity of the RNA-Dependent RNA Polymerase. J. Virol. 79: 14330-14338 [Abstract] [Full Text]  
  • Skiadopoulos, M. H., Biacchesi, S., Buchholz, U. J., Riggs, J. M., Surman, S. R., Amaro-Carambot, E., McAuliffe, J. M., Elkins, W. R., St. Claire, M., Collins, P. L., Murphy, B. R. (2004). The Two Major Human Metapneumovirus Genetic Lineages Are Highly Related Antigenically, and the Fusion (F) Protein Is a Major Contributor to This Antigenic Relatedness. J. Virol. 78: 6927-6937 [Abstract] [Full Text]  
  • MacPhail, M., Schickli, J. H., Tang, R. S., Kaur, J., Robinson, C., Fouchier, R. A. M., Osterhaus, A. D. M. E., Spaete, R. R., Haller, A. A. (2004). Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design. J. Gen. Virol. 85: 1655-1663 [Abstract] [Full Text]  
  • Newman, J. T., Riggs, J. M., Surman, S. R., McAuliffe, J. M., Mulaikal, T. A., Collins, P. L., Murphy, B. R., Skiadopoulos, M. H. (2004). Generation of Recombinant Human Parainfluenza Virus Type 1 Vaccine Candidates by Importation of Temperature-Sensitive and Attenuating Mutations from Heterologous Paramyxoviruses. J. Virol. 78: 2017-2028 [Abstract] [Full Text]  
  • McAuliffe, J. M., Surman, S. R., Newman, J. T., Riggs, J. M., Collins, P. L., Murphy, B. R., Skiadopoulos, M. H. (2004). Codon Substitution Mutations at Two Positions in the L Polymerase Protein of Human Parainfluenza Virus Type 1 Yield Viruses with a Spectrum of Attenuation In Vivo and Increased Phenotypic Stability In Vitro. J. Virol. 78: 2029-2036 [Abstract] [Full Text]  
  • Tang, R. S., Schickli, J. H., MacPhail, M., Fernandes, F., Bicha, L., Spaete, J., Fouchier, R. A. M., Osterhaus, A. D. M. E., Spaete, R., Haller, A. A. (2003). Effects of Human Metapneumovirus and Respiratory Syncytial Virus Antigen Insertion in Two 3' Proximal Genome Positions of Bovine/Human Parainfluenza Virus Type 3 on Virus Replication and Immunogenicity. J. Virol. 77: 10819-10828 [Abstract] [Full Text]  
  • Skiadopoulos, M. H., Schmidt, A. C., Riggs, J. M., Surman, S. R., Elkins, W. R., St. Claire, M., Collins, P. L., Murphy, B. R. (2002). Determinants of the Host Range Restriction of Replication of Bovine Parainfluenza Virus Type 3 in Rhesus Monkeys Are Polygenic. J. Virol. 77: 1141-1148 [Abstract] [Full Text]  
  • Neumann, G., Whitt, M. A., Kawaoka, Y. (2002). A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned?. J. Gen. Virol. 83: 2635-2662 [Abstract] [Full Text]  
  • Parks, C. L., Lerch, R. A., Walpita, P., Wang, H.-P., Sidhu, M. S., Udem, S. A. (2001). Comparison of Predicted Amino Acid Sequences of Measles Virus Strains in the Edmonston Vaccine Lineage. J. Virol. 75: 910-920 [Abstract] [Full Text]  
  • Parks, C. L., Lerch, R. A., Walpita, P., Wang, H.-P., Sidhu, M. S., Udem, S. A. (2001). Analysis of the Noncoding Regions of Measles Virus Strains in the Edmonston Vaccine Lineage. J. Virol. 75: 921-933 [Abstract] [Full Text]  
  • Haller, A. A., Miller, T., Mitiku, M., Coelingh, K. (2000). Expression of the Surface Glycoproteins of Human Parainfluenza Virus Type 3 by Bovine Parainfluenza Virus Type 3, a Novel Attenuated Virus Vaccine Vector. J. Virol. 74: 11626-11635 [Abstract] [Full Text]  
  • Durbin, A. P., Skiadopoulos, M. H., McAuliffe, J. M., Riggs, J. M., Surman, S. R., Collins, P. L., Murphy, B. R. (2000). Human Parainfluenza Virus Type 3 (PIV3) Expressing the Hemagglutinin Protein of Measles Virus Provides a Potential Method for Immunization against Measles Virus and PIV3 in Early Infancy. J. Virol. 74: 6821-6831 [Abstract] [Full Text]  
  • Tao, T., Skiadopoulos, M. H., Davoodi, F., Riggs, J. M., Collins, P. L., Murphy, B. R. (2000). Replacement of the Ectodomains of the Hemagglutinin-Neuraminidase and Fusion Glycoproteins of Recombinant Parainfluenza Virus Type 3 (PIV3) with Their Counterparts from PIV2 Yields Attenuated PIV2 Vaccine Candidates. J. Virol. 74: 6448-6458 [Abstract] [Full Text]  
  • Bailly, J. E., McAuliffe, J. M., Durbin, A. P., Elkins, W. R., Collins, P. L., Murphy, B. R. (2000). A Recombinant Human Parainfluenza Virus Type 3 (PIV3) in Which the Nucleocapsid N Protein Has Been Replaced by That of Bovine PIV3 Is Attenuated in Primates. J. Virol. 74: 3188-3195 [Abstract] [Full Text]  
  • Valsamakis, A., Auwaerter, P. G., Rima, B. K., Kaneshima, H., Griffin, D. E. (1999). Altered Virulence of Vaccine Strains of Measles Virus after Prolonged Replication in Human Tissue. J. Virol. 73: 8791-8797 [Abstract] [Full Text]